WO1999005121A1 - Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos - Google Patents
Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos Download PDFInfo
- Publication number
- WO1999005121A1 WO1999005121A1 PCT/ES1998/000212 ES9800212W WO9905121A1 WO 1999005121 A1 WO1999005121 A1 WO 1999005121A1 ES 9800212 W ES9800212 W ES 9800212W WO 9905121 A1 WO9905121 A1 WO 9905121A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- piperazinyl
- methoxy
- methoxypyrimidine
- pyrimidine
- hydrochloride
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to new acyl-piperazinyl-pyrimidines, of general formula (1), as well as their physiologically acceptable salts, to the processes for their preparation, to their application as medicaments in human and / or veterinary therapeutics and to the compositions Pharmaceuticals that contain them.
- the new compounds object of the present invention can be used in the pharmaceutical industry as intermediates and for the preparation of medicaments.
- Figure 1 shows the results of the sedative activity of compounds of this invention, determined by a decrease in locomotive activity.
- the present invention provides new compounds capable of causing conscious sedation, of acting as hypnotic, anticonvulsant, analgesic, muscle relaxant, antitussive, anxiolytic, antipsychotic, antidepressant, cerebral antiischemic, antimiginous agents, agents useful for sleep disorders, disease agents neurodegenerative, for cognitive disorders and Alzheimer's disease, and agents capable of inducing or maintaining general anesthesia, attending to the dose and route of administration.
- X is an oxygen or sulfur atom
- Rl is a C ⁇ -C alkoxy or trifluoromethyl radical
- R2 is a Ci-C ⁇ alkyl radical; cycloalkyl
- heterocycloalkyl consisting of a ring of 3 to 6 atoms comprising a heteroatom selected from an oxygen, sulfur and nitrogen atom, optionally N-substituted; phenyl optionally substituted by 1, 2 or 3 identical or different substituents selected from fluorine, chlorine, bromine, amino, acetamido, nitro, methyl, trifluoromethyl and methoxy; arylalkyl consisting of a Ci-C 3 alkyl group substituted by a phenyl radical optionally substituted by 1, 2 or 3 identical or different substituents selected from fluorine, chlorine, bromine, amino, acetamido, nitro, methyl, trifluoromethyl and methoxy; heteroaryl consisting of an optionally substituted heteroaromatic ring, of 5 or 6 members or of fused, optionally substituted heteroaromatic systems of 9 to 10 members consisting of 1 or 2 heteroatoms selected from oxygen, sulfur and nitrogen, said substituents being
- SUBSTITUTE SHEET by a heteroaryl radical consisting of an optionally substituted heteroaromatic ring, of 5 or 6 members or of fused heteroaromatic systems, optionally substituted, of 9 to 10 members consisting of 1 or 2 heteroatoms selected from oxygen, sulfur and nitrogen, said substituents being selected from fluorine, chlorine, bromine, amino, acetamido, nitro, methyl, trifluoromethyl and methoxy; and its physiologically acceptable salts.
- alkoxy Ci -
- C represents an OR 3 radical in which R 3 is a linear or branched saturated carbon chain of 1 to 4 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy or tert-butoxy.
- alkyl represents a radical derived from a saturated straight or branched chain hydrocarbon.
- Ci-Ce alkyl represents a straight or branched chain alkyl radical that includes 1 to 6 carbon atoms, such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tere-butyl, pentyl, isopentyl, neopentyl and hexyl.
- saturated C 3 -C 6 cycloalkyl represents a ring of 3 to 6 saturated carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
- heterocycloalkyl represents a ring of 3 to 6 atoms including a heteroatom such as an oxygen atom or a sulfur atom, such as for example a 2-aziridinyl, 2-tetrahydrofuryl, 3- tetrahydrofuryl radical, ' 2-tetrahydrothienyl, 3-tetrahydrothienyl, or an N-substituted or unsubstituted nitrogen atom, such as for example 2-azetidinyl, 2-pyrrolidinyl,
- SUBSTITUTE SHEET (RULE 26) 3-pyrrolidinyl, 2-piperidinyl, 3-piperidinyl or 4-piperidinyl.
- aryl represents a phenyl radical unsubstituted or substituted by 1, 2 or 3 same or different substituents such as fluorine, chlorine, bromine, amino, acetamido, nitro, methyl, trifluoromethyl or methoxy, such as 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-aminophenyl, 3-aminophenyl, 4-aminophenyl, 2-nitrophenyl, 3- nitrophenyl, 4-nitrophenyl, 2-acetamidophenyl, 3-acetamidophenyl, 4-acetamidophenyl, 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 2-acetamidophenyl, 3-acetamidophenyl, 4-ace
- arylalkyl represents a straight or branched chain of 1 to 3 carbon atoms and is substituted by an aryl radical, defined above as the term “aryl”, and which include substituents such as phenylmethyl, 1-phenylethyl, 2-phenylethyl , 3-phenylpropyl, as well as other radicals in which the aromatic ring is substituted by groups such as fluorine, chlorine, bromine, amino, acetamido, nitro, methyl, trifluoromethyl or methoxy.
- heteroaryl represents a substituted or unsubstituted 5- or 6-membered heteroaromatic ring or substituted fused heteroaromatic systems.
- SUBSTITUTE SHEET (RULE 26) or unsubstituted from 9 to 10 members consisting of 1 or 2 heteroatoms such as nitrogen, oxygen or sulfur, the substituents being groups such as fluorine, chlorine, bromine, amino, acetamido, nitro, methyl, trifluoromethyl or methoxy, such as for example 2 -furyl, 3-furyl, 2-thienyl, 3-thienyl, 3-methyl-2-thienyl, 5-methyl-2-thienyl, 3-methoxy-2-thienyl, 3-chloro-2-thienyl, 5-chloro -2-thienyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-indolyl, 3-indolyl, 2-benzo [b] thienyl, 3-benzo [b] thienyl, 3 -chloro-2-benzo [b] thienyl,
- heteroarylalkyl represents an alkyl group of 1 to 3 carbon atoms and is substituted by a heteroaryl radical, defined above as the term “heteroaryl”, and which include substituents such as 2-thienylmethyl, 2-benzo [b] thienylmethyl and 3- (4-chloropyrazolyl) propyl.
- the new compounds of the general formula (1) can have an asymmetric carbon atom and therefore can be prepared as optical isomers or racemates.
- the racemates of the compounds (1) can be resolved in their optical isomers by conventional methods, such as separation by chiral chromatography or by fractional crystallization of their diastereoisomeric salts. Likewise, they can also be obtained by asymmetric synthesis using chiral precursors.
- the present invention also relates to physiologically acceptable salts of the compounds of general formula (1), in particular the addition salts of mineral acids such as hydrochloric, hydrobromic, phosphoric, sulfuric, nitric and acidic acids.
- SUBSTITUTE SHEET organic such as p-toluenesulfonic acid or methanesulfonic acid.
- METHOD A The compounds of the general formula (1) can be prepared by reacting the chloropyrimidine derivative (3), where R. has the meaning indicated above, with a piperazine derivative of the general formula (4)
- the reaction is carried out in an organic solvent, such as a chlorinated organic hydrocarbon such as dichloromethane or chloroform, a linear or cyclic ether such as 1,2-dimethoxyethane, tetrahydrofuran or dioxane, an aprotic polar solvent such as pyridine, dimethylsulfoxide or dimethylformamide or any other suitable solvent to effect an aromatic nucleophilic substitution reaction.
- organic solvent such as a chlorinated organic hydrocarbon such as dichloromethane or chloroform, a linear or cyclic ether such as 1,2-dimethoxyethane, tetrahydrofuran or dioxane, an aprotic polar solvent such as pyridine, dimethylsulfoxide or dimethylformamide or any other suitable solvent to effect an aromatic nucleophilic substitution reaction.
- a mineral or organic base such as an aliphatic amine, preferably triethylamine or N-methylmorpholine and stirred at a temperature comprised
- SUBSTITUTE SHEET (RULE 26) between the ambient temperature and the boiling point of the solvent for a period between ten minutes and twenty four hours, the period between thirty minutes and five hours being the preferred conditions.
- Rl has the meaning indicated above with a carboxylic acid of the general formula R 2 COOH (6), in which R2 has the meaning indicated above, either with a salt of this same acid or also with a reactive derivative R 2 COY (7).
- salts include alkali metal salts such as sodium salt and potassium salt, alkaline earth salts such as calcium salt and magnesium salt, ammonium salt, and salts of organic bases such as triethylamine, trimethylamine, pyridine and picoline.
- SUBSTITUTE SHEET (RULE 26) Examples of reactive derivatives of the general formula R2COY (7) in which Y is a halogen atom preferably a chlorine atom or a bromine atom, an azido group (-N 3 ), a 1-imidazolyl group, a group 0- C0-R 4 , where R 4 can be an alkyl radical of 1 to 6 carbon or aryl atoms, preferably substituted by one or more halogen atoms, or an OR5 group where R 5 represents an aromatic group of one or two rings substituted by one or more halogen atoms or nitro radicals, with 4-nitrophenyl, 2,4-dinitrophenyl, pentachlorophenyl, pentafluorophenyl, 1-benzotriazolyl or N-succinimide groups being preferred.
- Y is a halogen atom preferably a chlorine atom or a bromine atom, an azido group (-N 3 ), a
- the compounds of the general formula (1) can be prepared directly by reacting the amine (5) with the carboxylic acid of the general formula R 2 COOH (7), preferring in this case that the reaction proceed in the presence of carbonyl group activation reagents such as N, N'-dicyclohexylcarbodiimide, diisopropylcarbodiimide or 3- (3-dimethylamino) propyl-l-ethylcarbodiimide.
- This reaction can also be carried out using the carbodiimides mentioned in the presence of 1-benzotriazole or N-hydroxysuccinimide.
- the acids of the general formula (7) and the amine of the formula (5) also react directly in the presence of N, N'-carbonyldiimidazole or of the propanophosphonic acid anhydride.
- the reaction is carried out in an organic solvent, such as a chlorinated organic hydrocarbon such as dichloromethane or chloroform, a linear or cyclic ether such as 1,2-dimethoxyethane, tetrahydrofuran or dioxane, an aprotic polar solvent such as pyridine, dimethylsulfoxide 'or dimethylformamide or any other suitable solvent.
- organic solvent such as a chlorinated organic hydrocarbon such as dichloromethane or chloroform
- a linear or cyclic ether such as 1,2-dimethoxyethane, tetrahydrofuran or dioxane
- an aprotic polar solvent such as pyridine
- dimethylsulfoxide 'or dimethylformamide any other suitable solvent.
- the reaction can be carried out in the presence of a mineral or organic base such as an amine
- SUBSTITUTE SHEET (RULE 26) aliphatic, preferably triethylamine or N-methylmorpholine and stirred at a temperature between room temperature and the boiling point of the solvent for a period between ten minutes and twenty four hours, the period between thirty minutes and five hours preferred conditions.
- the reaction is carried out in an organic solvent such as toluene, benzene, heptane, pyridine or tetrahydroforan.
- the reaction is kept under stirring at a temperature between room temperature and the boiling point of the solvent for a period between one hour and twenty four hours, it being preferable to carry out the reaction at 80se and for a period
- the salts of the compounds of the general formula (1) are prepared by reaction with a mineral acid such as hydrochloric, hydrobromic, phosphoric, sulfuric, nitric acid or with an organic acid such as p-toluenesulfonic acid or methanesulfonic acid within an appropriate solvent such as methanol, ethanol, ethyl ether, ethyl acetate, acetonitrile or acetone obtaining the corresponding salts with the usual precipitation or crystallization techniques.
- a mineral acid such as hydrochloric, hydrobromic, phosphoric, sulfuric, nitric acid
- organic acid such as p-toluenesulfonic acid or methanesulfonic acid
- an appropriate solvent such as methanol, ethanol, ethyl ether, ethyl acetate, acetonitrile or acetone obtaining the corresponding salts with the usual precipitation or crystallization techniques.
- the invention provides pharmaceutical compositions comprising, in addition to a pharmaceutically acceptable excipient, at least one compound of general formula (1) or one of its physiologically acceptable salts.
- the invention also relates to the use of a compound of general formula (1) and its physiologically acceptable salts in the preparation of a medicament with activity on the central nervous system in mammals, including man, particularly, in the preparation of a medicament with sedative, anticonvulsant, hypnotic and general anesthetic activity.
- Example 54 Preparation of 4-methoxy-2- (4-thiobenzoyl-1- piperazinyl) pyrimidine.
- the hypnotic activity of the products object of the invention has been studied by determining their capacity to enhance the sleep time induced by barbital, according to a modification of the method described by
- mice After fifteen minutes of administration of barbital (150 mg / kg, i.v.), the mice were treated with the product under study at an initial dose of 100 mg / kg (i.p.). From the most active products, the effective dose 50 (ED50) was determined. Table 2 shows the results of some of the products object of this invention taking meprobamate as a reference standard.
- mice The general anesthetic activity was studied in mice, injecting the product under study into the caudal vein. The onset and duration of sleep time was determined. The results for some of the products object of this patent are reflected in Table 3 and it is shown that they have a clear anesthetic activity in relation to the reference standard (Propofol), with subsequent recovery of the animals.
- the relaxing muscle activity of the products object of the invention has been studied by assessing their effect on the body tone and abdominal tone of the rats, following the method described by S. IRWING (Gordon
- Propofol 100 100 70 0 0 0 0
- the analgesic activity of the products object of the invention has been studied by assessing their effect in the test of contortions induced by phenylbenzoquinone in mice, following the method described by Siegmund, E., and cois. (Proc. Soc. Exp. Biol. Med. 1957, 95: 729-731).
- mice received the products under study, at different dose levels, and 1 hour later they received an i.p. of 5 mg / kg of phenyl-benzoquinone.
- the contortions of the mice were recorded during the next 15 minutes and compared with the contortions of the control group.
- Table 5 shows the DE-50 (dose
- Example DE-50 (mg / kg. S.c.) DE-50 (mg / kg, p.o.)
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
Claims
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA2000010370A UA59403C2 (uk) | 1997-07-21 | 1998-07-21 | Похідні ацилпіперазинілпіримідинів, спосіб їх одержання (варіанти), фармацевтична композиція та активний інгредієнт для виготовлення лікарського засобу |
ES98933660T ES2216297T3 (es) | 1997-07-21 | 1998-07-21 | Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos. |
DE69821623T DE69821623T2 (de) | 1997-07-21 | 1998-07-21 | Derivate von acyl-piperazinil-pyrimidinen, ihre herstellung und verwendung als medikament |
BR9810772-0A BR9810772A (pt) | 1997-07-21 | 1998-07-21 | Derivados de acil-piperazinil-pirimidinas, sua preparação e aplicação como medicamentos |
AT98933660T ATE259357T1 (de) | 1997-07-21 | 1998-07-21 | Derivate von acyl-piperazinil-pyrimidinen, ihre herstellung und verwendung als medikament |
EEP200000037A EE04151B1 (et) | 1997-07-21 | 1998-07-21 | Atsüülpiperasinüülpürimidiinide derivaadid, nendevalmistamine ja kasutamine ravimitena |
HU0002517A HUP0002517A3 (en) | 1997-07-21 | 1998-07-21 | Derivatives of acyl-piperazinil-pyrimidins, preparation thereof, pharmaceutical compositions containing them and their use as medicaments |
SI9820053A SI20269B (sl) | 1997-07-21 | 1998-07-21 | Derivati acil-piperazinil-pirimidinov, njihova priprava in uporaba kot zdravila |
CA002297417A CA2297417C (en) | 1997-07-21 | 1998-07-21 | Derivatives of acyl-piperazinyl-pyrimidines, their preparation and application as medicaments |
SK72-2000A SK284675B6 (sk) | 1997-07-21 | 1998-07-21 | Derivát acylpiperazinylpyrimidínu, spôsob jeho prípravy a farmaceutická kompozícia na jeho báze |
NZ502400A NZ502400A (en) | 1997-07-21 | 1998-07-21 | Derivatives of acyl-piperazinyl-pyrimidines |
EP98933660A EP1006110B8 (en) | 1997-07-21 | 1998-07-21 | Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments |
JP2000504120A JP2001510831A (ja) | 1997-07-21 | 1998-07-21 | アシル−ピペラジニル−ピリミジン誘導体、その製法および医薬としての応用 |
DK98933660T DK1006110T3 (da) | 1997-07-21 | 1998-07-21 | Derivater af acylpiperazinylpyrimidiner, fremstilling deraf og anvendelse som lægemidler |
KR10-2000-7000602A KR100514148B1 (ko) | 1997-07-21 | 1998-07-21 | 아실-피페라지닐-피리미딘 유도체 및 이의 제조방법 및약물로써의 용도 |
US09/462,880 US6372746B1 (en) | 1997-07-21 | 1998-07-21 | Derivatives of acyl-piperazinyl-pyrimidines, preparation thereof and application as medicaments |
AU83403/98A AU744633B2 (en) | 1997-07-21 | 1998-07-21 | Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments |
PL98338143A PL195632B1 (pl) | 1997-07-21 | 1998-07-21 | Pochodne acylopiperazynylopirymidyny, sposoby ichwytwarzania, kompozycje farmaceutyczne i ich zastosowanie jako leków |
IS5353A IS2076B (is) | 1997-07-21 | 2000-01-19 | Asýl-píperasínil-pýrimídínafleiður, framleiðsla og notkun þeirra sem lyfja |
NO20000294A NO314996B1 (no) | 1997-07-21 | 2000-01-20 | Derivater av acylpiperazinylpyrimidiner, farmasöytisk preparat inneholdendeslike derivater, deres fremstilling, og anvendelse tilfremstilling av legemidler |
LVP-00-08A LV12457B (en) | 1997-07-21 | 2000-01-21 | ACIL-PIPERAZINIL-PYRIMIDIN DERIVATIVES, THEIR ACQUISITION AND USE OF MEDICINES \ t |
HK01102218A HK1032958A1 (en) | 1997-07-21 | 2001-03-27 | Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES009701627A ES2125206B1 (es) | 1997-07-21 | 1997-07-21 | Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos. |
ESP9701627 | 1997-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999005121A1 true WO1999005121A1 (es) | 1999-02-04 |
Family
ID=8300152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES1998/000212 WO1999005121A1 (es) | 1997-07-21 | 1998-07-21 | Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos |
Country Status (34)
Country | Link |
---|---|
US (1) | US6372746B1 (es) |
EP (1) | EP1006110B8 (es) |
JP (1) | JP2001510831A (es) |
KR (1) | KR100514148B1 (es) |
CN (1) | CN1202087C (es) |
AR (1) | AR017254A1 (es) |
AT (1) | ATE259357T1 (es) |
AU (1) | AU744633B2 (es) |
BG (1) | BG64849B1 (es) |
BR (1) | BR9810772A (es) |
CA (1) | CA2297417C (es) |
CO (1) | CO5011090A1 (es) |
DE (1) | DE69821623T2 (es) |
DK (1) | DK1006110T3 (es) |
EE (1) | EE04151B1 (es) |
ES (2) | ES2125206B1 (es) |
GE (1) | GEP20033090B (es) |
HK (1) | HK1032958A1 (es) |
HU (1) | HUP0002517A3 (es) |
IN (1) | IN183820B (es) |
IS (1) | IS2076B (es) |
LT (1) | LT4728B (es) |
LV (1) | LV12457B (es) |
NO (1) | NO314996B1 (es) |
NZ (1) | NZ502400A (es) |
PL (1) | PL195632B1 (es) |
PT (1) | PT1006110E (es) |
RU (1) | RU2205827C2 (es) |
SI (1) | SI20269B (es) |
SK (1) | SK284675B6 (es) |
TW (1) | TW530056B (es) |
UA (1) | UA59403C2 (es) |
WO (1) | WO1999005121A1 (es) |
ZA (1) | ZA986437B (es) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032880A1 (es) * | 2000-10-20 | 2002-04-25 | Laboratorios Del Dr. Esteve, S.A. | Nuevos derivados de cianoaril (o cianoheteroaril)-carbonil-piperazinil-pirimidinas, su preparación y su aplicación como medicamentos |
WO2002072548A2 (en) * | 2001-03-09 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic compounds and their use as histamine h4 ligands. |
US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
WO2016084866A1 (ja) * | 2014-11-26 | 2016-06-02 | 持田製薬株式会社 | 新規ジアザビシクロ誘導体 |
WO2023006893A1 (en) * | 2021-07-30 | 2023-02-02 | Confo Therapeutics N.V. | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10035908A1 (de) * | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
US7390813B1 (en) * | 2001-12-21 | 2008-06-24 | Xenon Pharmaceuticals Inc. | Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents |
US20050119251A1 (en) * | 2001-12-21 | 2005-06-02 | Jian-Min Fu | Nicotinamide derivatives and their use as therapeutic agents |
DK1531822T3 (da) * | 2002-06-12 | 2009-12-07 | Chemocentryx Inc | 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser |
US7589199B2 (en) | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
US7842693B2 (en) * | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
AU2003246571B2 (en) * | 2002-06-29 | 2008-06-26 | Zentaris Gmbh | Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases |
US20040127395A1 (en) * | 2002-09-06 | 2004-07-01 | Desai Pragnya J. | Use of histamine H4 receptor modulators for the treatment of allergy and asthma |
CN1950082B (zh) | 2004-03-03 | 2013-02-06 | 凯莫森特里克斯股份有限公司 | 双环和桥连的含氮杂环化物 |
US7435831B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
AR051094A1 (es) * | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
US7767677B2 (en) | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
EP1827438B2 (en) * | 2004-09-20 | 2014-12-10 | Xenon Pharmaceuticals Inc. | Piperazin derivatives for inhibiting human stearoyl-coa-desaturase |
AU2005286790A1 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-CoA-desaturase (SCD) |
CN101084211A (zh) * | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为治疗剂的用途 |
MX2007003318A (es) | 2004-09-20 | 2007-05-18 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
AU2005286648A1 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
JP4958785B2 (ja) * | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体およびステアロイル−CoAデサチュラーゼインヒビターとしてのそれらの使用 |
AU2005286728A1 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
WO2007130075A1 (en) * | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
CA2616937A1 (en) * | 2005-07-29 | 2007-02-08 | F. Hoffman-La Roche Ag | Indol-3-yl-carbonyl-piperidin and piperazin derivatives |
WO2012031383A1 (zh) | 2010-09-06 | 2012-03-15 | 中国科学院广州生物医药与健康研究院 | 酰胺类化合物 |
EP2956441A4 (en) * | 2013-02-18 | 2016-11-02 | Scripps Research Inst | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0115713A1 (fr) * | 1982-11-09 | 1984-08-15 | Sanofi S.A. | (Pipérazinyl-1)-2 pyrimidines, leurs sels, procédé pour leur préparation et compositions pharmaceutiques en contenant |
US4547505A (en) * | 1983-03-25 | 1985-10-15 | Degussa Aktiengesellschaft | N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production |
EP0382637A1 (fr) * | 1989-02-09 | 1990-08-16 | Laboratorios Del Dr. Esteve, S.A. | Dérivés de pyrimidinyl-piperazinyl-alkyl azolès avec activité anxiolytique et/ou tranquillisante |
EP0497659A1 (fr) * | 1991-01-28 | 1992-08-05 | Laboratorios Del Dr. Esteve, S.A. | Dérivés d'aryl (ou hétéroaryl)-piperaz inyl-alkyl-azoles, leur préparation et leur application en tant que médicaments |
WO1994014779A1 (en) * | 1992-12-21 | 1994-07-07 | Smithkline Beecham Plc | Pyrimidinyl-piperazine derivatives and their use as medicaments |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0257102B1 (en) * | 1986-02-24 | 1997-11-19 | Mitsui Petrochemical Industries, Ltd. | Agents for treating neurophathy |
-
1997
- 1997-07-21 ES ES009701627A patent/ES2125206B1/es not_active Expired - Fee Related
-
1998
- 1998-07-16 AR ARP980103475A patent/AR017254A1/es active IP Right Grant
- 1998-07-17 CO CO98040807A patent/CO5011090A1/es unknown
- 1998-07-17 TW TW087111649A patent/TW530056B/zh not_active IP Right Cessation
- 1998-07-20 ZA ZA986437A patent/ZA986437B/xx unknown
- 1998-07-21 BR BR9810772-0A patent/BR9810772A/pt not_active Application Discontinuation
- 1998-07-21 AT AT98933660T patent/ATE259357T1/de not_active IP Right Cessation
- 1998-07-21 IN IN1272CA1998 patent/IN183820B/en unknown
- 1998-07-21 SI SI9820053A patent/SI20269B/sl not_active IP Right Cessation
- 1998-07-21 EE EEP200000037A patent/EE04151B1/xx not_active IP Right Cessation
- 1998-07-21 UA UA2000010370A patent/UA59403C2/uk unknown
- 1998-07-21 CN CNB988084589A patent/CN1202087C/zh not_active Expired - Fee Related
- 1998-07-21 CA CA002297417A patent/CA2297417C/en not_active Expired - Fee Related
- 1998-07-21 DE DE69821623T patent/DE69821623T2/de not_active Expired - Fee Related
- 1998-07-21 GE GEAP19985226A patent/GEP20033090B/en unknown
- 1998-07-21 SK SK72-2000A patent/SK284675B6/sk unknown
- 1998-07-21 HU HU0002517A patent/HUP0002517A3/hu unknown
- 1998-07-21 PT PT98933660T patent/PT1006110E/pt unknown
- 1998-07-21 ES ES98933660T patent/ES2216297T3/es not_active Expired - Lifetime
- 1998-07-21 EP EP98933660A patent/EP1006110B8/en not_active Expired - Lifetime
- 1998-07-21 NZ NZ502400A patent/NZ502400A/en unknown
- 1998-07-21 DK DK98933660T patent/DK1006110T3/da active
- 1998-07-21 KR KR10-2000-7000602A patent/KR100514148B1/ko not_active IP Right Cessation
- 1998-07-21 RU RU2000104007/04A patent/RU2205827C2/ru not_active IP Right Cessation
- 1998-07-21 US US09/462,880 patent/US6372746B1/en not_active Expired - Fee Related
- 1998-07-21 PL PL98338143A patent/PL195632B1/pl unknown
- 1998-07-21 JP JP2000504120A patent/JP2001510831A/ja active Pending
- 1998-07-21 WO PCT/ES1998/000212 patent/WO1999005121A1/es active IP Right Grant
- 1998-07-21 AU AU83403/98A patent/AU744633B2/en not_active Ceased
-
2000
- 2000-01-18 LT LT2000004A patent/LT4728B/lt unknown
- 2000-01-19 IS IS5353A patent/IS2076B/is unknown
- 2000-01-20 NO NO20000294A patent/NO314996B1/no unknown
- 2000-01-21 BG BG104100A patent/BG64849B1/bg unknown
- 2000-01-21 LV LVP-00-08A patent/LV12457B/en unknown
-
2001
- 2001-03-27 HK HK01102218A patent/HK1032958A1/xx not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0115713A1 (fr) * | 1982-11-09 | 1984-08-15 | Sanofi S.A. | (Pipérazinyl-1)-2 pyrimidines, leurs sels, procédé pour leur préparation et compositions pharmaceutiques en contenant |
US4547505A (en) * | 1983-03-25 | 1985-10-15 | Degussa Aktiengesellschaft | N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production |
EP0382637A1 (fr) * | 1989-02-09 | 1990-08-16 | Laboratorios Del Dr. Esteve, S.A. | Dérivés de pyrimidinyl-piperazinyl-alkyl azolès avec activité anxiolytique et/ou tranquillisante |
EP0497659A1 (fr) * | 1991-01-28 | 1992-08-05 | Laboratorios Del Dr. Esteve, S.A. | Dérivés d'aryl (ou hétéroaryl)-piperaz inyl-alkyl-azoles, leur préparation et leur application en tant que médicaments |
WO1994014779A1 (en) * | 1992-12-21 | 1994-07-07 | Smithkline Beecham Plc | Pyrimidinyl-piperazine derivatives and their use as medicaments |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032880A1 (es) * | 2000-10-20 | 2002-04-25 | Laboratorios Del Dr. Esteve, S.A. | Nuevos derivados de cianoaril (o cianoheteroaril)-carbonil-piperazinil-pirimidinas, su preparación y su aplicación como medicamentos |
ES2167276A1 (es) * | 2000-10-20 | 2002-05-01 | Esteve Labor Dr | Nuevos derivados de cianoaril (o cianoheteroaril)-carbonil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos. |
AU2001293877B2 (en) * | 2000-10-20 | 2007-01-04 | Laboratorios Del Dr. Esteve, S.A. | New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
US7300937B2 (en) | 2000-10-20 | 2007-11-27 | Laboratorios Del Dr. Esteve, S.A. | Derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
WO2002072548A2 (en) * | 2001-03-09 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic compounds and their use as histamine h4 ligands. |
WO2002072548A3 (en) * | 2001-03-09 | 2002-12-12 | Ortho Mcneil Pharm Inc | Heterocyclic compounds and their use as histamine h4 ligands. |
US6803362B2 (en) | 2001-03-09 | 2004-10-12 | Ortho-Mcneil Pharmaceutical Inc. | Heterocyclic compounds |
US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
WO2016084866A1 (ja) * | 2014-11-26 | 2016-06-02 | 持田製薬株式会社 | 新規ジアザビシクロ誘導体 |
WO2023006893A1 (en) * | 2021-07-30 | 2023-02-02 | Confo Therapeutics N.V. | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2216297T3 (es) | Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos. | |
JP5235887B2 (ja) | Rhoキナーゼ阻害剤 | |
AU2003287878A1 (en) | Quinoline compounds for use in mch receptor related disorders | |
JP2001510831A5 (es) | ||
EP0384228A1 (en) | Medicament for treating cerebral insufficiency diseases containing 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof | |
AU2009291309A1 (en) | Isoquinolinone derivatives as NK3 antagonists | |
EP1886996A1 (en) | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | |
EP2064185B1 (en) | 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions | |
JP2010514824A (ja) | 置換n−(4−シアノ−1h−ピラゾール−3−イル)メチルアミン誘導体、これらの調製およびこれらの治療的使用 | |
US7300937B2 (en) | Derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication | |
MXPA00000835A (es) | Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos | |
CZ2000143A3 (cs) | Deriváty acylpiperazinylpyrimidinů, způsob jejich výroby a farmaceutická kompozice na jejich bázi | |
AU2004316217A1 (en) | Cinnamic amides, process for their preparation, and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98808458.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-143 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 502400 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 722000 Country of ref document: SK Ref document number: 2000004 Country of ref document: LT |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2297417 Country of ref document: CA Ref document number: 1020007000602 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2000 20000008 Country of ref document: LV Kind code of ref document: A Ref document number: 2000 200000062 Country of ref document: RO Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200020000008 Country of ref document: LV |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/000835 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998933660 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 83403/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09462880 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998933660 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000004 Country of ref document: LT |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-143 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000004 Country of ref document: LT |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007000602 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 83403/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998933660 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007000602 Country of ref document: KR |